Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
University of Sulaimani College of Pharmacy
Dept. of Pharmaceutics5th stage – First Semester
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 1
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 2
Outlines
• Introduction
• Bulk characterization
• Crystallinity and polymorphism
• Hygroscopicity
• Fine particle characterization
• Bulk density
• Powder flow properties
• Solubility analysis
• Stability analysis
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 3
Introduction
• Preformulation is a phase of the research and development process where
the scientist characterizes the physical, chemical and mechanical properties
of a new drug substance.
• Preformulation involves a full understanding of the physicochemical
properties of drugs and other ingredients (excipients) in a dosage form and
how they may interact.
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 4
Introduction cont.
• Objective
• The preformulation investigations confirm that there are no significant
barriers to the compound’s development as a marketed drug.
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 5
Introduction cont.
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 6
Introduction cont.
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 7
Preformulation research area
Stability analysis
- Stability in toxicological formulation
- Solution stability
- Solid state stability
Solubility analysis
- Ionization constant pKa
- pH solubility profile
- Common ion effect Ksp
- Thermal effect
- Solubilization
- Partition coefficient
- Dissolution
Bulk characterization
- Crystallinity and polymorphism
- Hygroscopicity
- Fine particle characterization
- Bulk density
- Powder flow properties
Preformulation research area
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 8
Outlines
• Introduction
• Bulk characterization
• Crystallinity and polymorphism
• Hygroscopicity
• Fine particle characterization
• Bulk density
• Powder flow properties
• Solubility analysis
• Stability analysis
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 9
Crystallinity and polymorphism
Chemical compound
Habit Internal str.
Amorphous Crystal
Single entry
Polymorphs
Molecular adduct
Solvate (hydrate)
Inclusion compound
Cage (clathrate) Layer Channel
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 10
Crystallinity and polymorphism cont.
• Crystal habit and the internal structure of drug can affect bulk and
physicochemical properties, like flowability and chemical stability.
• Habit is the description of the outer appearance of a crystal.
• The internal structure is the
molecular arrangement within the
solid.
• In crystals atoms or molecules are
arranged in highly ordered form
and is associated with three-
dimensional periodicity.
• The repeating three-dimensional
patterns are called crystal lattices
Crystals
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 11
Crystalline vs amorphous
Crystalline forms Amorphous forms
(i) Crystalline forms have fixed internal
structure
(ii) The true density is higher.
(iii) They are more stable.
(iv) They have lesser solubility.
(v) They have lesser tendency to change
its form during storage.
(vi) They have melting points
(i) Amorphous forms do not have any
fixed internal structure
(ii) The true density is lower.
(iii) They are less stable.
(iv) They have greater solubility.
(v) They tend to revert to more stable
forms during storage.
(vi) They have a glass transition
temperature.
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 12
Crystallinity and polymorphism
Chemical compound
Habit Internal str.
Amorphous Crystal
Single entry
Polymorphs
Molecular adduct
Solvate (hydrate)
Inclusion compound
Cage (clathrate) Layer Channel
What is pseudopolymorphism?
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 13
Polymorphism
• Polymorphism is ability of a compound to crystallize as more than one
distinct crystalline species with different internal lattices.
• Chemical stability and solubility changes due to polymorphism can have an
impact on a drugs bioavailability.
• Many physicochemical properties vary with the internal structure of the
solid drugs, including melting point, density, hardness, crystal shape, and
vapor pressure.
• The highest-melting species is generally stable.
• High melting point = strong lattice = hard to remove a molecule = low
dissolution rate
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 14
Polymorphism cont.
• Barbiturates, steroids, and sulphonamides exhibit polymorphism.
• What is pseudopolymophism?
Comparison of mean blood serum level after theadministration of chloramphenicol palmitatesuspensions using varying ratios of the stable (α) andthe metastable (β) polymorphs. M 100% α; N, 25:75β:α; O, 50:50 β:α; P, 75:25 β: α; and L 100% β.
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 15
A. Non-Stoichiometric inclusion compounds (or adducts)
• In these crystals, solvent molecules are entrapped within the crystal lattice
and the number of solvent molecules are not included in stoichiometric
number.
1. Channel: When the crystal contains continuous channels in which the solvent
molecule can be included. e.g . Urea forms channel.
2. Layers:- Here solvent molecules are entrapped in between layers of crystals.
3. Clathrates (Cage):- Solvent molecules are entrapped within the cavity of the
crystal from all sides.
Crystallinity and polymorphism cont.
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 16
Crystallinity and polymorphism
Chemical compound
Habit Internal str.
Amorphous Crystal
Single entry
Polymorphs
Molecular adduct
Solvate (hydrate)
Inclusion compound
Cage (clathrate) Layer Channel
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 17
B. Stoichiometric inclusion compounds
• Solvate, is a molecular complex that has incorporated the solvent molecules
into specific sites within the crystal lattice.
• When the incorporated solvent is water, the complex is called a hydrate.
• Aqueous solubility of hydrous is usually less
than their anhydrous forms.
• The more soluble anhydrous form of
ampicillin produced higher and earlier
peaks in the blood serum levels than the
less soluble trihydrate form.
Crystallinity and polymorphism cont.
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 18
Analytical methods
Methods Material required per sample
MicroscopyDSC / DTAInfrared spectroscopy X-ray powder diffraction Scanning electron microscopy Thermogravimetic analysisDissolution/solubility analysis
1 mg2-5 mg2-20 mg500 mg2 mg10 mgmg to g
• Analytical methods for characterization of solid
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 19
Analytical methods
• Thermal analysis
• Differential scanning calorimetry (DSC) and differential thermal analysis
(DTA) measure the heat loss or gain resulting from physical or chemical
changes within a sample as a function of temperature.
• Examples of endothermic (heat-absorbing) processes are, boiling,
sublimation, vaporization, and chemical degradation.
• Crystallization are usually exothermic processes.
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 20
DSC
DSCEndotherm e.g. melting
Exotherm e.g. crystallizationStartup transient
Baseline shift (Tg)
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 21
Analytical methods
• Application
• To determine the purity of a sample
• To determine the number of polymorphs
• To determine the thermal degradation of a drug or excipients.
• To determine the glass-transition temperature (Tg) of a polymer
DSC, Carbamazepine form III
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 22
Thermogravimetric analysis (TGA)
• TGA measures changes in sample
weight as a function of time or
temperature.
• Desolvation and decomposition
processes are frequently monitored
by TGA.
Anhydrous form
Anhydrous:dihydrate
Dihydrate form
Anhydrous form
Anhydrous:dihydrate 10:1
Dihydrate form
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 23
Outlines
• Introduction
• Bulk characterization
• Crystallinity and polymorphism
• Hygroscopicity
• Fine particle characterization
• Bulk density
• Powder flow properties
• Solubility analysis
• Stability analysis
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 24
Hygroscopicity
• Water-soluble salt forms, have a tendency to adsorb atmospheric moisture.
• Moisture content can depend upon the atmospheric humidity, temperature,
and surface area exposure.
• Deliquescent materials adsorb sufficient water to dissolve completely, like
sodium hydroxide on a humid day.
• With most hygroscopic materials, changes in moisture level can greatly
influence many important parameters, such as
• Chemical stability
• Flowability
• CompatibilityAir
Solid particles
Hygroscopic water
Capillary water
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 25
• Hygroscopicity tests
• For the purpose of ‘handling’ data points from 0 to 24 hours are taken
• For the purpose of ‘storage’ data points from 0 to 12 weeks are taken.
• Significance of hygroscopicity test
• To decide special handling procedure
• The storage condition i.e. at low humidity environment.
• Special packaging e.g. with desiccant
Hygroscopicity cont.
desiccator
shallow container
saturated saltsolution
powder sample
Fig. 7
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 26
Outlines
• Introduction
• Bulk characterization
• Crystallinity and polymorphism
• Hygroscopicity
• Fine particle characterization
• Bulk density
• Powder flow properties
• Solubility analysis
• Stability analysis
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 27
Fine particle characterization
• Parameters those are measured:
• Particle size and size-distribution
• Surface area
• Surface morphology of the particles
• Bulk flow, formulation homogeneity, and dissolution are directly affected by
size, shape, and surface morphology of the drug particles.
• Instrumental methods of particle size characterization
A. Light microscope
B. Sieve analysis
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 28
Determination of specific surface area
• Brunauer, Emmett and Teller (BET) nitrogen adsorption method
• A layer of nitrogen molecules is adsorbed to the sample surface at –
196°C
• Once the surface is saturated, the sample is heated to room
temperature, the nitrogen gas is desorbed
• Each N2 molecule occupies an area of 16 A2
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 29
Characterization of surface morphology
• Scanning electron microscopy SEM.
• It is a microscope that produces an image by using an electron beam instead
of light that scans the surface of a specimen inside a vacuum chamber.
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 30
SEM
• Used to study topography crystallography
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 31
SEM
• Coating of samples is required in the field of electron microscopy to enable
or improve the imaging of samples.
• Samples are made conductive by coating with a very thin layer of gold by a
machine called sputter-coater.
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 32
Outlines
• Introduction
• Bulk characterization
• Crystallinity and polymorphism
• Hygroscopicity
• Fine particle characterization
• Powder density
• Powder flow properties
• Solubility analysis
• Stability analysis
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 33
Powder density
• Apparent bulk density is determined by pouring preserved (40 mesh) bulk
drug into a graduated cylinder and measuring the volume and weight as it
is.
• Tapped density is determined by placing a
graduated cylinder containing a known mass on a
mechanical tapper apparatus, which is operated
for a fixed number of taps (1000).
VolumeBulk
powder the of WeightDensityBulk Apparent =
volumeTapped
powdertheofWeightdensity Tapped =
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 34
Powder density cont.
• Knowing the anticipated dose and tapped formulation density, this figure
could be use to determine the appropriate size for a capsule formulation.
1.4
1.2
1.0
0.8
0.6
0.4
0.2
000
00
0
1
2345
0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1
600 mg
400 mg
200 mg
cap
sule
vo
lum
e m
L
Cap
sule
siz
e
Packed density g/mL
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 35
Powder density cont.
• Particle density is defined as the ratio of particle mass to the particle volume,
including the pores within the particle, but still excluding the gaps between
particles.
• Particle density is measured by the mercury intrusion method.
• Solvents of varying densities could be used to measure true density of the
powder as well!
• Benzene, water and CCl4 could be used
A pycnometer is a typical apparatus for the liquid replacement method
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 36
Powder density cont.
• True density refers to the ratio of the mass of the particle to its actual volume,
excluding pore volume and the volume of the gap between particles.
• True density is determined with helium pycnometer.
• If a powder is compacted into tablets using high pressure, the resultant density
is very close to the true density
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 37
Powder density cont.
• Porosity refers to the ratio of the volume of the pore interior and the space
between particles to the total volume of the powder.
• For tablets with higher porosity, water can penetrate the tablets, more readily
resulting in a faster disintegration time.
Porosity = 1 −𝑏𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
𝑡𝑟𝑢𝑒 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
Preformulations I Industrial Pharmacy I, Dr. rer nat Rebaz Ali 38
Thank you for your attention!